Blueprint Medicines (BPMC)
BPMC
Oncology
BiotechSign Signal Grade
C
Signal Grade
52.7/100 composite signal score
Composite of clinical trial activity, dilution exposure, publications, short interest, and insider transactions — all from verified public filings.
Insider Buying
0
Publications
100
Clinical Activity
83
Pipeline Overview
- Therapeutic Focus
- Oncologysrc
Clinical Trial Activity
9
Clinical Trials
(ClinicalTrials.gov aggregate)
(ClinicalTrials.gov aggregate)
2 Phase 1, 4 Phase 2, 1 Phase 3, 1 Phase 4
Trial Phase Breakdown
5
PubMed Publications
0
Catalyst Records
ClinicalTrials.gov aggregate as of 2026-10-16. ClinicalTrials.gov
Recent News & SEC Filings
- SEC 8-K 8-K - Current report
- SEC 8-K 8-K - Current report
- SEC 8-K 8-K - Current report
- SEC 8-K 8-K - Current report
- SEC 8-K 8-K - Current report
Headlines from public sources. BiotechSign does not endorse or verify linked content.
Recent Publications
- Next-generation tumor-agnostic targets on the horizon. — Trends Cancer 2026 Sep 21 PMID 42767904
- Access to early-phase oncology trials: Trajectories and outcomes of more than 26,000 patients referred to a high-volume phase I unit. — Eur J Cancer 2026 Sep 17 PMID 42762559
- Molecular Response, Event-Free Survival, and Treatment-Free Remission in Myeloproliferative Neoplasms: Update and Review with Insights from MPN Asia 2026. — Curr Hematol Malig Rep 2026 Sep 18 PMID 42758401
- Reappraisal of Cisplatin vs Carboplatin Treatment for Solid Tumors: An Umbrella Meta-Analysis. — JAMA Netw Open 2026 Sep 1 PMID 42752909
- Canakinumab or emavusertib for anemia in lower-risk MDS: results of the CANFIRE and LUCAS phase 2, open-label, multicenter trials. — Commun Med (Lond) 2026 Sep 16 PMID 42749863
Get real-time catalyst alerts, analyst signals, dilution risk tracking, and full pipeline data for Blueprint Medicines.
Full BPMC Dashboard Sign Up FreePrimary Sources
This page reports only records present in the BiotechSign source payload as of the generation date. It does not infer drug efficacy, clinical outcome probability, approval odds, revenue, market size, or unreported regulatory events.